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Abstract: Background and objectives: In children, acute infection is the most common cause of visits to
the emergency department. Although most of them are self-limiting, mortality due to severe bacterial
infections (SBI) in developed countries is still high. When the risk of serious bacterial infection
is too high to ignore, yet too low to justify admission and hospital observation, clinicians try to
improve diagnostic accuracy by performing various laboratory tests. The aim of the study was to
investigate whether an early inflammatory cytokine and chemokine panel can add information in
diagnostics of SBI and assessment of efficacy of early therapies in hospitalized children with fever.
Methods: This study included 51 children with febrile infections that were admitted to the emergency
department (ED). Clinical examination and microbiological and radiological tests were used as
reference standards for the definition of SBI. Study population was categorized into two groups:
(1) patients with SBI (n = 21); (2) patients without SBI (n = 30). Inflammatory cytokine and chemokine
panels were analyzed from the first routine blood samples at hospital admission and after 24 h.
Results: Out of 12 cytokines and chemokines, only Eotaxin and granulocyte colony-stimulating factor
(G-CSF) had statistically significant differences between groups at the time of inclusion. Receiver
operator characteristic analysis to predict SBI showed an area under the curve (AUC) of 0.679 for
G-CSF. Conclusions: Analysis of inflammatory cytokine profiles may provide additional information
in early diagnostics of SBI.
Keywords: serious bacterial infection; children; inflammation; cytokine
1. Introduction
In children, acute infection is the most common cause of visit in the primary care or emergency
department, and although most are self-limiting, mortality due to severe bacterial infections (SBI) in
developed countries is still high [1]. Due to low incidence, non-specific initial presentation, and risk
of rapid deterioration, the assessment of children with acute infection is difficult [2]. There have
been studies and reviews about clinical decision-making rule and laboratory tests which could help
distinguish between self-limiting, viral infection, and SBI [2,3].
In 2013, Verbakel et al. published a systematic review about accuracy of clinical prediction tools
for SBI, where they conclude that none of the clinical predictions’ tools examined provided perfect
clinical accuracy [2]. Van den Bruel et al. have published a systematic review about diagnostic value of
laboratory tests in identifying SBI; their conclusion was that measurement of inflammatory markers
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in emergency department can be diagnostically useful, but different cut-off values should be used
whether clinicians want to rule out or confirm SBI [3].
In 2002, The International Consensus Conference on Pediatric Sepsis and Organ Dysfunction
produced consensus clinical definitions of systemic inflammatory response syndrome (SIRS) and sepsis
in children [4], which became a landmark of diagnostics of paediatric sepsis, and was thought to aid in
identifying serious bacterial infections. According to this, patients were not required to have positive
blood cultures to be diagnosed with sepsis. However, it has its limitations, which include an excessive
focus on inflammation cascade and inadequate specificity and sensitivity of SIRS, as well as a model of
sepsis following a continuum through severe sepsis to septic shock [5].
Even after thorough clinical assessment, clinicians are left with uncertainty where the risk of
serious bacterial infection is too high to ignore, yet too low to justify admission and hospital observation.
In these cases, clinicians try to improve diagnostic accuracy by performing various laboratory tests [3].
C reactive protein (CRP) is the most widely used diagnostic and prognostic marker, despite its
limitation due to late appearance and persistence for relatively longer periods [6]. In addition, CRP
and procalcitonin (PCT) have limited ability to distinguish SBI from other nonbacterial inflammatory
conditions, and they are not useful in predicting outcome [7]. Use of “emerging” biomarkers for early
diagnosis of SBIs and sepsis has been widely studied. Meem et al., in a review of published data
about diagnostic markers of neonatal sepsis, have found PCT, interleukin 6 (IL-6), interleukin 8 (IL-8),
interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), cluster of differentiation 64 (CD64),
and soluble intercellular adhesion molecules (sICAM) to be the most promising [6]. IL-6 and IL-8 have
been shown to have elevated levels in sepsis, and are also associated with severity and outcome [8].
Furthermore, there are published data confirming that combining information from several
inflammatory markers improves accuracy in distinguishing bacterial and nonbacterial causes of
inflammation [9]. A good biomarker for diagnostics of SBI would have diagnostic, prognostic,
and follow-up of therapy characteristics, and would also be rapidly and easily used in clinical practice [10].
In light of this, the aim of the study was to investigate whether an early inflammatory cytokine
and chemokine panel could provide additional information in diagnostics of SBI, and also help to
assess the efficacy of therapies in children with SBI.
2. Materials and Methods
Patient recruitment took place from October 2011 to December 2013 in Children’s Clinical
University hospital, Riga, Latvia.
The inclusion criteria were: hospitalized children with fever, aged from 1 month to 17 years. Patients
were assessed by physicians according to hospital’s standard of care.
SBI, at the emergency department and during the later revision of clinicians, was defined based
on available clinical, imaging, and later also on microbiological data, as having either bacteraemia,
pneumonia (radiographically confirmed), meningitis, osteomyelitis, complicated urinary tract infection,
skin/soft tissue infection, culture positivity of usually sterile body fluid, or clinical diagnosis by
radiology (pneumonia, osteomyelitis, intra-abdominal infection) [11]. The group of patients with fever
but without SBI included children with upper respiratory tract infections and viral gastroenteritis.
Patients with SBI were divided into age groups (1–12 months, 12–60 months, 60–144 months and
144–216 months) and patient controls without SBI of the same age group were matched.
The exclusion criteria were antibacterial therapy within the last 48 h, immunodeficiency, chronic
liver or kidney illness, vaccination within 5 days before the start of the illness, congenital metabolic
defects, chromosomal anomalies, and use of corticosteroids or immunosuppressant medications. Other
exclusion factors from the study were obesity, diabetes mellitus, chronic inflammatory diseases, such
as rheumatoid arthritis, systemic lupus erythematosus, vasculitis, inflammatory bowel disease, heart
diseases, renal or liver diseases, or malignancies and other diseases which are known to be associated
with significant changes of anti- and pro-inflammatory biomarkers, including surgery or trauma within
the preceding 30 days.
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Informed consent was obtained from patients’ parents and additionally from patients themselves,
if applicable. The study protocol was approved by the Committee of Ethics of Riga Stradin’s University
(No 2./06.10.2011). All patients had received the standard of care according to hospital guidelines.
All patients had blood samples drawn at the time of inclusion and after 24 h. Plasma CRP were
measured in all patients according to hospital’s standards. Patients also had 5 mL of blood drawn for
serum centrifugation, after which the serum was then frozen, and all patients’ samples were analysed
at once. In all patients, there were the same inflammatory cytokine and chemokine panels (soluble
apoptosis- stimulating fragment (sFAS), soluble vascular cell adhesion molecule (sVCAM-1), total
plasminogen activator inhibitor type 1 (tPAI1), IL-8, INF gamma, tumor necrosis factor alpha (TNF-α),
Eotaxin-1, granulocyte colony-stimulating factor (G-CSF), interleukin-1 receptor antagonist (IL-1ra),
interferon-inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1). Cytokine panels
were analyzed using Luminex® xMAP® technology, which is a multiplex assay approach (Luminex
200™, Merck Millipore, Germany).
Statistical analysis was performed using IBM SPSS 22, and included descriptive statistics with
median values, standard deviation, and range for continuous variables where appropriate. To test for
differences between the compared groups, Mann-Whitney tests were used for continuous variables
as appropriate, and the chi-squared test was used for categorical variables. Receiver-operating
characteristic (ROC) curves were developed for each of the continuous biomarkers presenting the area
under the curve, including the 95% CI for each biomarker. The Youden’s index was used to determine
the cut-off values for each indicator to determine sensitivity and specificity. A two-tailed p value <0.05
was statistically significant.
3. Results
In total, out of 140 patients with fever who were hospitalized from the emergency department,
124 met the inclusion criteria. 54 patients, whose parents consented to the study, were included.
Patients were then divided into 2 groups based on possible presence or absence of SBI after clinical
evaluation. At the end of the study data from 3 patients was discarded, as their inclusion samples
were haemolytic, thus, not suitable for analysis.
The baseline characteristics of the study sample are depicted in Table 1.
Table 1. Characteristics of study population.
Title 1 Severe Bacterial Infection (SBI)Patients (n = 21)
Patients without
SBI (n = 30)
Age, median, months (±SD) 43.0 ± 63.9 30.5 ± 59.62
Sex, percent (n) 42.9% (9) males57.1% (12) females
63.3% (19) males
36.7% (11) females
Inclusion day after symptom onset, median (±SD) 5 ± 2.48 3 ± 3.50
C-reactive protein (CRP), median (±SD), mg/L 131.95 ± 111.94 35.65 ± 61.3
Length of hospitalization, median (±SD) 8 ± 7.81 3 ± 2.33
Antibacterial therapy 100% (21) 50% (15)
In the SBI group, 15 patients had pneumonia, 3 had complicated urinary tract infections, 2 patients
had osteomyelitis, and one had meningitis. In the SBI group blood cultures were drawn in 38.1% (8),
only one patient with osteomyelitis had a positive blood culture for Staphylococcus aureus. There were
statistically significant differences between SBI and non-SBI groups in the length of hospitalization
and antibacterial therapy.
All patients were discharged from the hospital at the end of the treatment.
At the inclusion of the study for all patients, all inflammatory markers were tested, and groups
were compared. The numerical values of inflammatory cytokines in both groups can be seen in Table 2.
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Table 2. Median, range and comparison of cytokines and chemokines between patients with and
without severe bacterial infections (SBI) at the time of inclusion.
Inflammatory Cytokines, Median (min–max) pg/mL SBI (n = 21) Patients without SBI(n = 30) p Value
Soluble apoptosis-stimulating fragment (sFas) 3356.23 (1606.69–6791.45) 3740.37 (1925.82–6832.95) p = 0.153
Soluble vascular cell adhesion molecule (sVCAM1) 1306.07 (568.63–5042.88) 1010.95 (392.91–4197.20) p = 0.243
Total plasminogen activator inhibitor type 1 (tPAI-1) 147.80 (72.01–353.81) 136.43 (56.80–327.74) p = 0.389
Interleukin 8 (IL-8) 12.6 (1.56–158.57) 10.2 (4.00–35.70) p = 0.723
Interleukin 10 (IL-10) 30.10 (16.22–7127.79) 40.35 (9.71–3365.79) p = 0.841
Interferon gamma (INF-gamma) 16.9 (0.13–172.36) 13.6 (0.34–838.20) p = 0.688
Tumor necrosis factor alpha (TNF-alfa) 13.97 (0.67–100.41) 13.99 (6.42–35.24) p = 0.566
Eotaxin 50.23 (14.80–107.76) 73.61 (13.50–107.76) p = 0.035
Granulocyte colony-stimulating factor (G-CSF) 504.69 (18.88–10,000) 187.27 (29.19–10,000) p = 0.031
Interleukin-1 receptor antagonist (IL1ra) 4.94 (3.20–158.60) 16.1 (2.00–125.17) p = 0.601
Interferon-inducible protein-10 (IP10) 977.78 (218.74–10,000) 1070.93 (100.60–10,000) p = 0.836
Monocyte chemoattractant protein-1 (MCP1) 319.05 (126.35–4788.12) 411.28 (39.15–5763.23) p = 0.168
We found statistically significant differences in Eotaxin and G-CSF levels between groups at the
time of inclusion. Eotaxin levels were in fact higher in patients without SBI. As G-CSF levels were
significantly higher in patients with SBI, we calculated its ROC-curve, which is graphically depicted in
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Figure 1. Area under the receiver-operating chara teristic (ROC) curve for granulocyte colony-stimulating
factor (G-CSF).
G-CSF area under the ROC curve (AUC) was 0.679 (±0.08, 95% CI 0.534–0.803) with a p = 0,025, it
had sensitivity of 52.38% and specificity of 86.67%.
As the next step, we performed paired sample analysis using ilcoxon signed rank test and
compared the significance of changes of these markers at the time of inclusion and after 24 h of
treatment. There were no significant changes in inflammatory cytokines in a 24 h time period in the
non-SBI group. In the SBI group, statistically significant changes between time of inclusion and 24 h
the following markers showed sFAS (p = 0.041), IL-10 (p = 0.027), INFγ (p = 0.016), Eotaxin (p = 0.027),
G-CSF (p < 0.001), and IP-10 (p = 0.012). Eotaxin showed significant increase in a 24 h time period,
whilst all the other cytokines decreased after 24 h. The numerical values are depicted in Table 3.
Medicina 2019, 55, 4 5 of 7
Table 3. Comparison of inflammatory cytokine patterns at the time of inclusion and after 24 h in
patients with severe bacterial infections (SBI).
Inflammatory Cytokines, Median (min-max) pg/mL Time of Inclusion After 24 h p Value
Soluble apoptosis-stimulating fragment (sFas) 3356.23 (1606.69–6791.45) 3530.31 (1925.82–7553.48) p = 0.041
Soluble vascular cell adhesion molecule (sVCAM1) 1306.07 (568.63–5042.88) 919.10 (628.18–4859.74) p = 0.078
Total plasminogen activator inhibitor type 1 (tPAI-1) 147.80 (72.01–353.81) 154.99 (92.44–286.00) p = 0.383
Interleukin 8 (IL-8) 12.6 (1.56–158.57) 8.78 (2.89–105.36) p = 0.0383
Interleukin 10 (IL-10) 30.10 (16.22–7127.79) 26.12 (6.47–3385.94) p = 0.027
Interferon gamma (INF-gamma) 16.9 (0.13–172.36) 5.18 (0.13–120.94) p = 0.016
Tumor necrosis factor alpha (TNF-alfa) 13.97 (0.67–100.41) 12.42 (4.74–73.12) p = 1.000
Eotaxin 50.23 (14.80–107.76) 64.02 (20.49–122.77) p = 0.027
Granulocyte colony-stimulating factor (G-CSF) 504.69 (18.88–10,000) 129.75 (29.19–2074.56) p < 0.001
Interleukin-1 receptor antagonist (IL1ra) 4.94 (3.20–158.60) 3.20 (1.66–77.85) p = 0.146
Interferon-inducible protein-10 (IP10) 977.78 (218.74–10,000) 576.579 (161.67–10,000) p = 0.012
Monocyte chemoattractant protein-1 (MCP1) 319.05 (126.35–4788.12) 309.16 (65.71–4327.81) p = 0.383
4. Discussion
The diagnostics of SBI are still challenging although there are new tests and clinical scores available.
The diagnosis of SBI is complicated by its non-specific clinical symptoms, and their variability; failure
to diagnose and promptly treat SBI results in significant morbidity and mortality [12]. In addition, the
complex pathophysiology and great patient-to-patient variability in SBIs needs to be considered.
When comparing inflammatory cytokine profiles, we found statistically significant differences
between groups only in levels of Eotaxin and G-CSF. There were also significant differences in some of
the inflammatory cytokines after 24 h of inclusion, and, of course, therapy.
Eotaxin-1 has not been studied either as a diagnostic nor as a prognostic marker for SBIs. There are
publications about levels of Eotaxin-1 in parasitic infections [13], in which patients with tuberculosis
had significantly higher levels than controls[14]. There have been no large studies about its use on
diagnostics of SBI. Eotaxin-1 has also been studied in cases of serious acute respiratory illness, where
its levels were significantly higher if a respiratory virus was present in the broncho-alveolar lavage
fluid [15]. This could partially explain our results, where Eotaxin-1 was significantly higher in patients
without SBI, as this group was mainly composed of patients with viral respiratory infections. It is
unclear why there was a significant increase in Eotaxin levels in children with SBI after 24 h of therapy,
whilst all the other significant changes between cytokine levels showed a decrease.
In patients with SBI, several inflammatory markers (sFAS, Eotaxin) showed a significant increase
after 24 h. Although all patients in this group received antibacterial therapy, it is unclear how this
inflammatory response correlates with therapy. G-CSF, IL-10, INF γ and IP-10 showed a significant
decrease over 24 h in patients with SBI.
G-CSF has been largely studied as a treatment for sepsis and septic shock. In preterm neonatal
patients, rhG-CSG adjunctive therapy has been shown to decrease mortality [16]. In an animal study,
performed by Gao et al., a combination of biomarkers was measured in rats after induced sepsis.
The results showed that a combination of different biomarkers improved the diagnostic accuracy [17].
Increased G-CSF concentrations have been shown to be predictive of worsening organ dysfunction
in sepsis and had good accuracy in predicting early mortality [18]. G-CSF has not been studied as a
diagnostic marker.
There are published data about IP-10 as a possible diagnostic marker. It has been studied as a
diagnostic marker in urine in cases of neonatal sepsis, where it showed statistically significant increase
in neonates with bacterial infections [19].
IL-10, an anti-inflammatory cytokine which prevents the excess pro-inflammatory response, has
been widely studied in different populations. High levels of IL-10 in patients with septic shock have
been correlated with poor prognosis. However, an appropriate IL-10 response has been shown to have
a protective effect against inflammation. Our patients with SBI had a significant decrease in IL-10
levels after 24 h of therapy. As we had no mortality in this patient group, we can speculate that this
decrease is a logical step in the inflammatory pathway as a normal response to therapy.
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This study had several limiting factors, the most important being the small patient population.
This is mostly attributable to difficulties of patient enrolment and technical difficulties of venous blood
sampling in children. In addition, we had no control group of healthy children, which could provide
baseline levels for inflammatory cytokines. For more accurate determination of significance of these
markers in diagnostics of SBI, further studies with bigger patient population are necessary.
5. Conclusions
This study added information about inflammatory cytokine panels in hospitalized children with
and without SBI and their dynamic changes after 24 h of therapy. We also detected significant changes
in levels of G-CSF between patients with and without SBI, which could improve diagnostic accuracy
in patients with SBI.
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